ReviewFrontiers in physiology2026
Skeletal muscle-heart crosstalk in chronic kidney disease: hierarchical signaling networks underlying myocardial metabolic reprogramming and fibrotic remodeling.
Review in Frontiers in physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease is a major complication of chronic kidney disease (CKD) and often develops alongside skeletal muscle wasting and sarcopenia. These abnormalities are usually studied as separate consequences of CKD, but they may also be linked through shared systemic stressors and inter-organ communication. CKD exposes both skeletal muscle and the myocardium to a persistent uremic milieu characterized by toxin retention, chronic inflammation, oxidative stress, hypoxia, and metabolic disturbance. In this setting, skeletal muscle-heart crosstalk may shift from an adaptive homeostatic program to a maladaptive network that contributes to myocardial metabolic dysfunction and fibrotic remodeling. Under physiological conditions, and especially during exercise, skeletal muscle releases myokines and extracellular vesicles carrying miRNAs, proteins, and other regulatory molecules that support myocardial substrate utilization, mitochondrial function, and repair responses. In CKD, however, altered myokine profiles and dysregulated extracellular vesicle cargoes may act on cardiomyocytes, cardiac fibroblasts, and endothelial cells, promoting impaired metabolic flexibility, extracellular matrix deposition, and progressive cardiac remodeling. The heart may also feed back on skeletal muscle through cardiac-derived endocrine signals and neurohumoral pathways, further reinforcing muscle wasting and systemic dysfunction. In this review, we summarize current evidence on skeletal muscle-heart communication under physiological, exercise-related, and CKD-associated conditions, with emphasis on myokines, extracellular vesicles, and miRNA-mediated signaling. Better definition of this axis may help identify biomarkers and therapeutic targets for CKD-associated sarcopenia and cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.